John Holyoake

Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada.

Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.